If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAston Martin Lagonda Regulatory News (AML)

Share Price Information for Aston Martin Lagonda (AML)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 136.00
Bid: 133.30
Ask: 165.00
Change: 0.00 (0.00%)
Spread: 31.70 (23.781%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 136.00
AML Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - ARRIS GROUP INC

18 Dec 2015 13:39

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

Barclays PLC.

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

ARRIS GROUP INC

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

17 Dec 2015

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

YES PACE PLC

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: ORD
Interests Short Positions
Number (%) Number (%)
(1) Relevant securities owned
and/or controlled: 95,529 0.07% 181,315 0.12%
(2) Cash-settled derivatives:
651,419 0.44% 0 0.00%
(3) Stock-settled derivatives (including options)
and agreements to purchase/sell: 12,100 0.01% 28,200 0.02%
(4)
TOTAL: 759,048 0.52% 209,515 0.14%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant Purchase/sale Number of Price per unit
security securities
ORD Purchase 16 29.8283 USD
ORD Purchase 42 29.8700 USD
ORD Purchase 100 30.2400 USD
ORD Purchase 100 29.9100 USD
ORD Purchase 100 29.9700 USD
ORD Purchase 140 29.9600 USD
ORD Purchase 270 30.0781 USD
ORD Purchase 300 30.0450 USD
ORD Purchase 398 29.9582 USD
ORD Purchase 400 30.0412 USD
ORD Purchase 456 29.9194 USD
ORD Purchase 500 29.8890 USD
ORD Purchase 500 29.8410 USD
ORD Purchase 800 29.8093 USD
ORD Purchase 2,020 29.8000 USD
ORD Purchase 2,227 29.9518 USD
ORD Purchase 3,400 29.9115 USD
ORD Purchase 3,508 29.9644 USD
ORD Purchase 12,627 29.9764 USD
ORD Purchase 72,533 30.2000 USD
ORD Sale 16 29.8283 USD
ORD Sale 99 29.9300 USD
ORD Sale 100 29.9450 USD
ORD Sale 140 29.9600 USD
ORD Sale 200 29.8700 USD
ORD Sale 200 30.0950 USD
ORD Sale 284 29.9491 USD
ORD Sale 456 29.9195 USD
ORD Sale 456 29.9194 USD
ORD Sale 600 29.9900 USD
ORD Sale 800 29.9237 USD
ORD Sale 902 30.0674 USD
ORD Sale 1,000 29.8650 USD
ORD Sale 1,326 29.8092 USD
ORD Sale 1,411 29.9317 USD
ORD Sale 1,720 29.8000 USD
ORD Sale 4,902 30.0670 USD
ORD Sale 5,702 29.9111 USD
ORD Sale 6,505 29.9686 USD
ORD Sale 72,533 30.2000 USD

(b) Cash-settled derivative transactions

Class of relevant security Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type

e.g. American, European etc.

Expiry date Option money paid/ received per unit

(ii) Exercise

Class of relevant security Product description

e.g. call option

Exercising/ exercised against Number of securities Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing

e.g. subscription, conversion

Details Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

YES

Date of disclosure:

18 DEC 2015

Contact name:

Jay Supaya

Telephone number:

020 7773 0635

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

143221.01

SUPPLEMENTAL FORM 8 (OPEN POSITIONS)

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.

Note 5(i) on Rule 8 of the Takeover Code (the “Code”)

1. KEY INFORMATION

Full name of person making disclosure:

Barclays PLC.

Name of offeror/offeree in relation to whose relevant securities the disclosure relates:

ARRIS GROUP INC

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class Product Writing, Number Exercise Type Expiry
of description purchasing, of price date
relevant selling, securities per unit
security varying etc to which
option
relates
ORD Put Options Written 400 30.0000 American 18 Dec 2015
ORD Call Options Written -1,200 30.0000 American 18 Dec 2015
ORD Call Options Written -100 25.0000 American 20 May 2016
ORD Call Options Purchased 3,800 30.0000 American 20 May 2016
ORD Put Options Purchased -8,000 32.5000 American 20 May 2016
ORD Call Options Purchased 7,700 30.0000 American 15 Jan 2016
ORD Call Options Written -6,600 32.5000 American 20 May 2016
ORD Put Options Written 200 27.5000 American 15 Jan 2016
ORD Call Options Written -12,100 32.5000 American 15 Jan 2016
ORD Call Options Written -200 27.5000 American 20 May 2016

3. AGREEMENTS TO PURCHASE OR SELL ETC.

Full details should be given so that the nature of the interest or position can be fully understood:

It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151218005437/en/

Copyright Business Wire 2015

Date   Source Headline
9th May 20247:00 amRNSIssue of equity to satisfy employee share awards
8th May 202412:12 pmRNSAGM voting results
2nd May 20244:11 pmRNSDirector/PDMR Shareholding
1st May 20242:59 pmRNSESEF Annual Report 2023
1st May 20247:00 amRNSQ1 results for three months ended 31 March 2024
8th Apr 20249:00 amRNSAnnual Report 2023 and Notice of AGM
28th Mar 20244:10 pmRNSDirector Declaration
22nd Mar 20248:28 amRNSAppointment of New Chief Executive Officer
13th Mar 20246:16 pmRNSSuccessful pricing of £1.15 billion refinancing
12th Mar 20243:33 pmRNSHolding(s) in Company
11th Mar 20247:36 amRNSLaunch of Notes Offering
4th Mar 20249:05 amRNSIssue of equity to satisfy share awards
28th Feb 20247:00 amRNSPreliminary Results year ended 31 December 2023
20th Dec 20239:32 amRNSHolding(s) in Company
20th Dec 20239:31 amRNSHolding(s) in Company
8th Nov 20233:46 pmRNSHolding(s) in Company
8th Nov 20233:41 pmRNSHolding(s) in Company
8th Nov 20238:00 amRNSHolding(s) in Company
7th Nov 20233:23 pmRNSHolding(s) in Company
3rd Nov 202310:18 amRNSDirector/PDMR Shareholding
2nd Nov 20238:00 amRNSAdmission of shares and total voting rights
1st Nov 20237:00 amRNS3rd Quarter Results
30th Oct 20237:00 amRNSDirectorate Change
3rd Oct 20232:14 pmRNSDirector/PDMR Shareholding
3rd Oct 20232:13 pmRNSDirector/PDMR Shareholding
3rd Oct 20232:10 pmRNSDirector/PDMR Shareholding
3rd Oct 20232:10 pmRNSDirector/PDMR Shareholding
3rd Oct 20232:07 pmRNSHolding(s) in Company
29th Sep 20237:00 amRNSIncreased investment by Yew Tree Consortium
19th Sep 202311:53 amRNSResult of Meeting
29th Aug 202312:01 pmRNSPublication of Circular and Notice of GM
4th Aug 20234:45 pmRNSHolding(s) in Company
4th Aug 20231:05 pmRNSDirector/PDMR Shareholding
4th Aug 202312:43 pmRNSDirector/PDMR Shareholding
4th Aug 202312:33 pmRNSDirector/PDMR Shareholding
4th Aug 202312:32 pmRNSDirector/PDMR Shareholding
4th Aug 202312:21 pmRNSHolding(s) in Company
1st Aug 20237:00 amRNSResult of Equity Issue
31st Jul 20234:41 pmRNSRetail Offer
31st Jul 20234:40 pmRNSProposed Share Placing
28th Jul 20237:00 amRNSAppointment of Non-executive Director
26th Jul 20232:49 pmRNSTotal Voting Rights
26th Jul 20237:00 amRNSHalf-year Report
14th Jul 202312:18 pmRNSHolding(s) in Company
10th Jul 20234:34 pmRNSReplacement Listing and Total Voting Rights
10th Jul 20238:56 amRNSAdditional Listing and Total Voting Rights
6th Jul 20238:16 amRNSHolding(s) in Company
3rd Jul 20237:00 amRNSAdmission of New Shares for Warrant exercise
27th Jun 20237:00 amRNSCapital Markets Day 2023
26th Jun 20237:00 amRNSAston Martin Lagonda and Lucid Group, Inc.

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.